Grants
Grants funding pages collect matching grants, scholarships, benefits, fellowships, and other programs from the FindMyMoney.App directory. Use this page to compare current opportunities, then verify deadlines and eligibility on the official source before applying.
RFA-AI-27-012: Coccidioidomycosis Collaborative Research Centers (P01 Clinical Trial Not Allowed)
NIH/NIAID’s 2026 RFA-AI-27-012 supports multi-disciplinary Coccidioidomycosis Collaborative Research Centers focused on Valley fever vaccine progress, with up to three to four P01 awards funded in FY 2027.
RFA-CA-27-021: Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
NCI’s RFA-CA-27-021 supports advanced and widely adopted cancer informatics resources through U24 sustained-support awards, with $1.8 million committed in FY 2027 across two awards.
RFA-DC-25-003: Cooperative Agreement for In Vivo High-Resolution Inner Ear Imaging (U01, Clinical Trial Required)
NIH/NIDCD funding for investigator-initiated high-risk clinical trials that advance non-invasive in vivo imaging of the inner ear and support translation of imaging technologies into clinical care.
RFA-DC-25-005: In Vivo High-Resolution Imaging for Inner Ear Visualization (R01, Clinical Trial Optional)
This NIH NIDCD RFA funds projects that develop higher-resolution structural or functional imaging for the living human inner ear, with up to $500,000 direct costs per year and FY 2026/2027 allocations.
RFA-DC-26-001: Early-Stage Dissemination and Implementation Research in Communication Disorders (R21 Clinical Trial Optional)
NIH's NIDCD reissue asks for early-stage dissemination and implementation (D&I) research to move evidence-based communication-disorder interventions toward real-world use through a two-year, R21-format mechanism.
RFA-FD-25-007: Laboratory Flexible Funding Model (LFFM)
FDA's Laboratory Flexible Funding Model Cooperative Agreement supports state and public laboratories to expand food safety and food defense testing capacity through structured analytical tracks in microbiology, chemistry, and radiochemistry.
RFA-FD-25-020: Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01)
FDA’s Office of Orphan Products Development supports clinical trials for rare disease products through OOPD RFA-FD-25-020, including recurring 2026 and 2027 due dates with up to $650,000 annually in base project support.
RFA-HG-25-009: Supporting Talented Early Career Researchers in Genomics (R01)
NIH/NHGRI reissues an R01-style NOFO for highly promising Early Stage Investigators (ESIs) building independent genomics programs, with a maximum direct-cost budget of $400,000 per year and up to a five-year project term.
RFA-HL-26-016: Catalyze Enabling Technologies and Transformative Platforms for HLBS Research (R33)
NIH's NHLBI Catalyze R33 opportunity funds enabling technologies and transformative platforms in heart, lung, blood, and sleep (HLBS) research with strong validation milestones and measurable performance measures.
RFA-HL-26-020: Catalyze: Product Definition Medical Device Prototype Optimization (R33)
NHLBI Catalyze RFA-HL-26-020 funds late-stage prototype optimization for medical devices, diagnostics, and research tools for heart, lung, blood, and sleep disorders via R33 awards.